Lianhua Qingwen is a traditional herbal medicine that the Chinese regime has been promoting for reducing symptoms such as fever and sore throat in mild COVID cases.

Recently, the controversial state-backed influenza drug has been accused of causing liver injury or even liver failure. As a result, Yiling Pharmaceutical, its manufacturer, lost a total market value of about $3.73 billion (26 billion yuan) in 12 days.

As Da Ji Yuan reported on December 27, the company’s shares have dropped constantly due to drug shortages and soaring prices. 

As of December 23, the company’s market value dropped to $8.67 billion (60.38 billion yuan) from its peak of $12.4 billion (86.46 billion yuan) on December 12.

Regarding the efficacy of the drug, the outlet noted that Shenzhen Health Commission published a study on its official account, stating that Lianhua Qingwen capsules are less practical than canned yellow peaches.

Moreover, the health agency also claimed that the capsule could only win in damaging the liver but does not exceed peaches’ benefits in every other aspect.

In response to this, the communist regime immediately deleted the article.

Similarly, Chinese media outlet Sohu published an article on December 13 saying that Yan Yuping, chief physician of the Department of Liver Diseases at Jinan Hospital of Infectious Diseases, confirmed three patients with liver failure registered in the hospital the same morning due to taking Lianhua Qingwen capsules and ibuprofen simultaneously. 

Sohu also faced the same consequence. The report disappeared for no reason not long after.

Yiling Pharmaceutical already refuted this news on December 18. Still, its COVID-19 treatment efficacy has been openly questioned by well-known people, including biologist Rao Yi, a Chinese healthcare platform named Dingxiang Yisheng, and Wang Sicong, the son of one of China’s wealthiest men.

According to Forbes, Chinese authorities have been promoting the herbal remedy for mild COVID cases. As a result, Yiling shares had almost quadrupled since the pandemic first started in 2020.

However, Dingxiang Yisheng has published an article saying that there is no official evidence to prove the efficacy of Lianhua Qingwen in preventing the coronavirus.

The report also said that the World Health Organization has not yet approved the capsules for treating COVID. 

As reported by Apollo News, China is facing a severe medication shortage.

On December 10, the Chinese Ministry of Industry and Information Technology had to send letters calling for assistance in producing Lianhua Qingwen capsules for influenza. 

In addition, the supply scarcity also prompted Chinese state-owned Sinopharm to sign an agreement on December 15 to purchase and distribute Paxlovid, Pfizer’s latest COVID-19 pill.

China News reported that Chinese citizens must buy medicines from their friends and relatives overseas.

This is because, in China, retailers sell these products at prices way higher than those abroad.

Let’s take Doliprane as an example. This drug costs only $2.30 (16 yuan) per box in France. But in China, sells it for as high as $23 (160 yuan), which is ten times more expensive.

No one knows where that leaves citizens looking for medication.

Sign up to receive our latest news!

By submitting this form, I agree to the terms.